Increased risk of clinically significant CMV reactivation in CAR T-cell therapy recipients receiving immunosuppression. (A) The 180-day incidence of clinically significant CMV reactivation in the entire cohort. (B-G) The 180-day incidence of clinically significant CMV reactivation in patients receiving CAR T-cell therapy by (B) degree of CRS, (C) corticosteroid use, (D) tocilizumab use, (E) use of ≥2 immunosuppressants, (F) anakinra use, and (G) degree of ICANS. The number of subjects was 94.